Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

This study tests whether combining two drugs — rituximab (a standard treatment) and zanubrutinib (a newer targeted therapy) — works better than rituximab alone for people with certain types of slow-growing B-cell lymphomas that have not been treated before, including marginal zone lymphoma (MZL) and follicular lymphoma (FL). **You may be eligible if...** - You have been newly diagnosed with either marginal zone lymphoma (MZL) or follicular lymphoma (FL) and have not yet received treatment - Prior antibiotic therapy for H. pylori-related MZL or antiviral therapy for hepatitis C-related MZL is allowed - You have a tissue sample confirming your diagnosis available - Your lymphoma requires systemic treatment **You may NOT be eligible if...** - You have received prior systemic therapy for your lymphoma - You have a different type of lymphoma not covered by the study - You have serious organ dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.